Two strategies were developed to test the hypothesis that failure to generate HIV-1 bNAbs was, at least in part, the result of HIV-1 mimicry of host determinants and the consequent purging by immune tolerance of those B cells best able to bind the shared host/HIV-1 epitopes. First, V(D)J knockin (KI) mice expressing bNAb BCR were generated to determine whether the auto-/polyreactivity of bNAb BCR determined in vitro was sufficient to activate immune tolerance as determined by clonal deletion, receptor editing, and/or B-cell anergy (Table 1) . Second, the bNAbs were used to identify and isolate host molecules that were structurally mimicked by neutralizing epitopes of HIV-1 Env. Failure in either test would have disproven the "immune tolerance" hypothesis for the lack of protective humoral immunity to HIV-1.
| EVIDENCE FOR HOST CONTROL OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES

| BNAb expression by knockin mouse lines
1 first demonstrated that the gp41 membrane proximal external region (MPER) bNAbs, 2F5, and 4E10, were polyreactive for human host lipids and several proteins. In 2010, Verkoczy et al. 4 demonstrated that 2F5 bNAb V H DJ H knockin (KI) mice exhibited profound deletion (95%) of maturing B cells in bone marrow and that the great majority of B cells in the periphery were anergic. Since then, a number of bNAb KI mouse models have been developed and studied both in the presence and absence of HIV-1 vaccine immunization (Table 1; Verkoczy, Tian, and Alt, this volume).
| gp41 MPER bnAbs
We have previously shown that the 2F5 bNAb that binds to the proximal MPER of HIV-1 Env, has reactivity for lipids, and avidly binds to an ELDKWA amino acid epitope present in both gp41 Env and an enzyme of tryptophane metabolism, kynureninase (Kynu). initially activated, but rapidly disappeared following additional immunizations. 7 This immunization protocol did induce serum antibody responses to the ELDKWA site in Kynu, presumably by breaking tolerance to this phylogenetically conserved epitope. 5, 9 Moreover, the immunized macaques that mounted Kynu-specific antibody responses also generated MPER-reactive antibodies that bound the 2F5 gp41 epitope; these gp41 MPER antibodies were limited, however, in neutralization potency by a limiting ceiling of HCDR3 hydrophobicity obtainable by vaccination-induced somatic mutation that is needed for 2F5 and 2F5-like antibodies to react with virion lipids to effectively neutralize HIV-1.
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Similar to bNAb 2F5, the 4E10 MPER bNAb exhibits broad polyreactivity with lipids and host proteins and a high degree of autoreactivity for an RNA splicing factor, splicing factor 3b subunit 3 (SF3B3). 
| CD4 binding site bnAbs
CD4 binding site (CD4-bs) bnAbs can be divided into two major groups based on how the antibody paratope interacts with the CD4-bs epitope. CD4-bs bnAbs that bind primarily via contacts in the third complementarity determining region of the heavy chain (HCDR3)
include the CH103, HJ16, VRC13, and VRC16 antibodies; a second group, including the VRC01 and 3BNC60, ANC131, and CH235 bnAbs bind largely via contact residues in HCDR2, the second H-chain CDR. 
| VRC01-class bNAbs
The prototype VRC01 antibody is not polyreactive against human proteins but does have high avidity for the phylogenetically conserved ubiquitin protein ligase E3A (UBE3A This late immune control may reflect negative selection in the germinal center microenvironment.
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In contrast to the VRC01 KI line generated by Tian et al. 
| CH103-class bnAbs
The CH103 bnAb binds to the CD4-bs via residues in HCDR3 and in its original description it, but not the UCA CH103 was observed to be polyreactive in clinical autoantibody assays. 22 A subsequent study using human protein microarrays 9 also found the mutated, mature form of CH103 to be significantly polyreactive and, like three other CD4-bs bnAbs (VRC01, VRC02, and CH106) react with UBE3A
with avidities proportional to their neutralization potency ( Figure 1 ).
This association raises the possibility that CD4-bs bnAbs of both the HCDR3 and HCDR2 classes may be controlled by central and/or peripheral (eg, germinal center) immune tolerance acting to suppress autoreactivity to UBE3A.
| V1V2-glycan bnAbs
The V1V2 bnAbs are generally characterized by exceptionally long HCDR3 domains: the CH01 V1V2 bnAb HCDR3 contains 24 amino acid residues, 23 the PG9 and PG16 bnAbs have HCDR3s of 28 residues, 24 and bnAb -VRC26 has an extremely long HCDR3 of 35 amino acids. 25 These contrast substantially to the 15 residue mean value for human HCDR3 lengths. Of four CH01 V1V2-glycan bnAbs isolated, CH03 reacted with histones, ribonucleoprotein, and centromere autoantigens, while CH01, CH02, and CH03 bound to the hepatitis C E2 glycoprotein and to whole cell lysates of intestinal flora. 26 V1V2
bnAbs CAP256-VRC26, PG9 and PG16 were not described to be polyreactive 24 but B cell antigen-receptors with long HCDR3 regions are commonly culled from the primary B-cell repertoire at the first immune tolerance checkpoint. [27] [28] [29] Thus, V1V2-glycan antibodies with very long HCDR3s may be limited by deletion in bone marrow, and polyreactivity of more mature antibodies may limit their maturation at the later stages of affinity maturation.
| V3-glycan bnAbs
Relatively little is known with regard to the auto-or polyreactivity of V3-glycan bNAbs or their ability to affect B-cell development and maturation. KI mice with the DH270 V3-glycan lineage are under construction (Tian, M and Alt, F unpublished), but to date, a limited number of studies on V3-glycan UCAs and affinity matured bnAbs have not demonstrated polyreactivity. V3-glycan bNAbs, however, often carry long HCDR3 motifs; for example, the PGT121 bNAb has a long HCDR3 and is capable of inhibiting CD4 binding to Env gp120 even though it does not bind to the CD4-bs. 30 It is thought that PGT121
binding induces an allosteric change in the HIV-1 Env that minimizes or precludes CD4 binding. ; for these epitopes, HIV-1 mimicry of host antigens is no longer a hypothesis. We think it likely that for the induction of robust bNAb activity in the setting of vaccination, vaccine formulations and adjuvants will need to be designed to transiently overcome tolerance controls and provided in a sequence that promotes normally disfavored pathways of clonal selection and complete development of bNAb B cell lineages.
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| Identification of human proteins mimicked by HIV-1
Knowing that the 2F5 and 4E10 KI mice exhibited patterns of B-cell deletion and anergy consistent with the action of immune tolerance, 4,6,10 Yang et al. 5 used the bNAbs themselves to search for murine proteins that were structurally similar to the HIV-1 Env epitopes recognized by each antibody by immunoprecipitation and mass spectroscopy. In this way, we identified 15 cytoplasmic proteins reproducibly bound 2F5 and three proteins recognized by 4E10. 5 In an independent screen for 2F5 and 4E10 ligands, we used a commercial protein microarray that covers 9400 human proteins, to identify any binding by the 2F5 and 4E10 bNAbs to human proteins; remarkably, This study found that 45% (10/22) bNAbs (VRC07, NIH45-46, CH103, CH106, CH98, CH31, 4E10, PG9, PGT125, and PGT128) were significantly polyreactive for human proteins and at least one polyreactive bNAb was present in each of the four neutralization classes:
CD4bs, MPER, V1/V2, and V3-glycan. 5, 9 In contrast, only a single (1/9; 11%) nNAb (HG131) recovered from a vaccinee (RV144 ALVAC prime, AIDSVAX B/E protein boost) was found to be polyreactive. The different frequencies of polyreactivity among bNAbs and nNAbs was highly significant whether analyzed by lineages or single Abs. The different frequencies of poly-or autoreactive bNAbs (59%) vs nNAbs (22%) was significant and uncorrelated with mutation frequencies per se. 9 Importantly, four CD4bs bNAbs, VRC01, VRC02, and CH106 and CH103, bound human UBE3A more avidly than the control Ab (Figure 1 ). Although VRC01 alone bound UBE3A ≥500-fold above the 151K control, VRC02 and CH106 bound UBE3A ≥300-fold more avidly while CH103 bound UBE3A ≈100-fold more avidly than 151K. Binding to UBE3A was confirmed for all four bNAbs in stringent condition ELISA ( Figure 1B ). on conventional T cells is inhibitory, whereas on T Reg cells, it enhances proliferation and survival.
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That CTLA-4 and PD-1 regulate distinct inhibitory pathways and have non-overlapping mechanisms of action suggested that concurrent combination therapy with both might be more efficacious than either alone. Indeed, this prediction was demonstrated in mice and later supported by outcomes in human clinical trials. 41, 42 Combination treatments are also being developed to enable blockade of multiple inhibitory pathways, such as LAG-3 53, 54 and TIM-3 55, 56 ; importantly checkpoint blockade has also been combined with cancer vaccines 57-59 so as to 'fuel the engine (with vaccination) and release the brake (with checkpoint inhibitors)'. remarkably, these framework mutations may be necessary for bNAb breadth and potency. 72 Somatic mutation can also generate de novo hotspots for activation-induced cytidine deaminase (AID) activity in V(D)J rearrangements, creating template sites prone to insertion/deletion mutations 73 ; in some cases, the occurrence of an insertional event is critical to acquisition of bNAb activity. 73 Thus, merely by limiting GC persistence, T FReg activity might block the possibility vaccine-induced bNAb production.
| VACCINE TRANSIENT IMMUNE MODULATION FOR BNAB INDUCTION
The very properties that appear to be required for bNAb activity, extended HCDR3 regions, high frequencies of V(D)J mutation, poly-or autoreactivity are also properties that disfavor B-cell development and survival. Given that immunological tolerance shapes the primary BCR repertoire, only B cells that have been vetted by tolerance are available to respond to vaccines; for vaccine antigens that mimic selfantigens, the pool of mature B cells that can respond will be reduced.
These predicted effects have been amply demonstrated in bNAb KI mouse lines (Table 1 ) and are consistent with atypical pathways of bNAb evolution normally proscribed by the effects of peripheral tolerance. 3 The unusually low efficiency with which immunization elicits bNAbs implies that bNAb B cells are the products of disfavored clonal evolution. In consequence, we propose that checkpoint inhibitors and other agents that transiently relax immunological tolerance may provide tools for increasing HIV-1 vaccine efficacy. Even should this approach not prove to be useful in large-scale vaccination efforts, they may point the way toward understanding why even our best vaccine antigens are unable to provide significant protection to at risk populations.
| First tolerance checkpoint
Immune tolerance purges developing B cells that express antigen receptors (BCR) that are self-reactive. At least three mechanisms for central B cell tolerance have been identified: apoptotic deletion, receptor editing, and functional inactivation or anergy. 74 Despite long study, the mechanisms that drive these tolerizing actions have not yet been made clear. It came, therefore, as a surprise when expression of activation-induced cytidine deaminase (AID) in immature and transitional B cells in mice and humans is genetically linked to the first tolerance checkpoint. 75, 76 In the absence of AID, autoreactive immature/ transitional-1 (T1) B cells are inefficiently purged and exhibit increased resistance to receptor-induced apoptosis.
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These substantial effects were surprising in that AID expression in the immature/T1 B-cell pools is only 3% of germinal center (GC) B cells. 75, 77 Noting that Meffre and colleagues had found that equally unlikely candidate for the first tolerance checkpoint in signaling components of TLRs, MyD88, and IRAK4, 78 we have demonstrated that 
| Peripheral control of bNAb responses
| CONCLUSIONS
Since 
